News tagged ‘Leukemia’ clear
Dana-Farber scientists have safely shut down breast cancer and a form of leukemia in mice by targeting abnormal proteins to which the cancers are "addicted."
Tags: BasicResearch, BreastCancer, Leukemia
Dana-Farber and Broad Institute researchers for the first time are able to show the past, present, and future of CLL tumors.
Tags: BasicResearch, Genetics, Leukemia
- An analysis of two dozen clinical studies finds most adults with
poor-risk and intermediate-risk acute myeloid leukemia benefit from
allogeneic stem cell transplants.
Tags: BasicResearch, StemCellTransplant, Leukemia
- Researchers report that patients with high-risk acute AML who received a
cancer vaccine after a stem cell transplant had few complications and
mounted a strong immune system attack on the disease.
Tags: StemCellTransplant, Leukemia
The pre-cancerous blood disorder myelodsysplastic syndrome (MDS) affects between 35,000 and 55,000 people in the United States. Dana-Farber's David Steensma, MD, discusses MDS and its treatment.
Tags: StemCellTransplant, Leukemia
Stand Up To Cancer announced the second round of awards for its Innovative Research Grants Program, naming the 13 young scientists who will receive a combined $9.74 million to conduct high-risk/high-reward translational cancer research. Dana-Farber's Catherine J. Wu, MD, is one of the recipients.
Tags: Grants, Honors, Prevention, Leukemia
- Scientists have found a way to switch off the behavior of a protein that drives uncontrolled cell growth in tumors.
Tags: Leukemia
Dana-Farber researchers have developed a method for determining how ready acute myeloid leukemia cells are to die, a finding that may enable oncologists to choose more effective treatments for their patients.
Tags: BasicResearch, StemCellTransplant, Leukemia
- A test developed by Dana-Farber scientists is the first to identify
which malignant blood cells are highly vulnerable to a promising type of
experimental drugs that unleash pent-up cell suicide factors to destroy
the cancer.
Tags: BasicResearch, Leukemia
Dana-Farber investigators led a phase 1 trial in which a new oral targeted drug, idelalisib, (GS-1101), showed the potential to stave off the need for additional treatments for relapsed or treatment-resistant CLL.
Tags: BasicResearch, Leukemia